In the Media

CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects

September 29, 2021/0 Comments/in In the Media /by malford

Bob Linke, CEO of Osmol, was interviewed for the CEO Leadership Series sponsored by Ashton-Tweed, a life sciences executive search firm Mr. Linke discusses OSM-0205, the company’s ground-breaking CIPN treatment and managing a virtual team during the COVID-19 pandemic.

BioWorld News to Note for May 13, 2021

May 13, 2021/0 Comments/in In the Media /by malford

Osmol Therapeutics Inc., of New Haven, Conn., said it initiated IND-enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase I study is projected by the company to begin in 2022.

Home Site Map Privacy Policy Terms of Use Contact

designed and managed by Body1

Home Site Map Privacy Policy Terms of Use Contact

designed and managed by Body1

Home
Site Map
Privacy Policy
Terms of Use
Contact

designed and managed by Body1